Effect of vitamin D therapy in addition to amitriptyline on migraine attacks in pediatric patients.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of migraine, published as a clinical trial.

The purpose of this study was to investigate the effect of supplementary vitamin D therapy in addition to amitriptyline on the frequency of migraine attacks in pediatric migraine patients.

Why It Was Studied

Patients were classified into four groups on the basis of their 25-hydroxyvitamin D [25(OH)D] levels.

Calcium, phosphorus alkaline phosphatase, parathormone, and 25(OH)D levels were also determined before and during treatment.

Who Took Part

The age groups tagged for this paper are children and teenagers, both men and women.

Fifty-three children 8-16 years of age and diagnosed with migraine following the International Headache Society 2005 definition, which includes childhood criteria, were enrolled.

What Was Measured

Patients were classified into four groups on the basis of their 25-hydroxyvitamin D [25(OH)D] levels.

Calcium, phosphorus alkaline phosphatase, parathormone, and 25(OH)D levels were also determined before and during treatment.

The subject headings attached to it are Alkaline Phosphatase, Amitriptyline, Analgesics, Non-Narcotic, Analysis of Variance, Calcium, Chi-Square Distribution and Drug Combinations.

What This Means in Plain Language

This is a clinical trial of Vitamin D, K2, Magnesium and Zinc in people with migraine.

The publication is from 2014 (Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica), a journal based in Brazil.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Migraine research.